These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 20524323)
1. Use of bortezomib for prevention and treatment of rejection in sensitized patients. Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D Clin Transpl; 2009; ():499-503. PubMed ID: 20524323 [TBL] [Abstract][Full Text] [Related]
2. Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases. Cooper JE; Wiseman AC; Chan L Clin Transpl; 2009; ():455-9. PubMed ID: 20524314 [No Abstract] [Full Text] [Related]
5. Bortezomib rescue in refractory acute humoral rejection--report of a case. Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V Clin Transpl; 2009; ():431-2. PubMed ID: 20524310 [No Abstract] [Full Text] [Related]
6. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC. Pavlakis M Clin Transpl; 2009; ():343-5. PubMed ID: 20524296 [TBL] [Abstract][Full Text] [Related]
7. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction. Stuckey LJ; Kamoun M; Chan KM Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499 [TBL] [Abstract][Full Text] [Related]
8. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection. Hardinger KL; Murillo D Clin Transpl; 2011; ():401-8. PubMed ID: 22755438 [TBL] [Abstract][Full Text] [Related]
9. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection. Al Meshari K Clin Transpl; 2009; ():385-6. PubMed ID: 20524302 [No Abstract] [Full Text] [Related]
10. Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases. Mai HL; Cesbron A; Brouard S; Blanchol G; Cantarovich D; Dantal J; Hourmant M; Lino M; Meurette A; Gosselin M; Abbadie O; Soulillou JP; Giral M Clin Transpl; 2009; ():361-8. PubMed ID: 20524299 [No Abstract] [Full Text] [Related]
11. A summary of bortezomib use in transplantation across 29 centers. Everly MJ Clin Transpl; 2009; ():323-37. PubMed ID: 20524294 [TBL] [Abstract][Full Text] [Related]
17. Bortezomib for acute humoral rejection in two repeat transplant recipients. Hardinger KL; Alford K; Murillo D Clin Transpl; 2009; ():479-83. PubMed ID: 20524319 [TBL] [Abstract][Full Text] [Related]
18. Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line? Lee I; Constantinescu S; Gillespie A; Swami A; Birkenbach M; Leech S; Silva P; Karachristos A; Daller JA; Sifontis NM Clin Transpl; 2009; ():425-9. PubMed ID: 20524309 [No Abstract] [Full Text] [Related]
19. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239 [TBL] [Abstract][Full Text] [Related]
20. Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants. Weston M; Rolfe M; Haddad T; Lopez-Cepero M Clin Transpl; 2009; ():393-9. PubMed ID: 20524304 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]